MAI Capital Management
ESPR icon

MAI Capital Management’s Esperion Therapeutics ESPR Stock Holding History

MAI Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-88
Closed -$242 – 2880
2026
Q1 		$242 Buy
88
+58
+193% +$184 ﹤0.01% 4579
2025
Q4 		$111 Hold
30
– – ﹤0.01% 4150
2025
Q3 		$80 Hold
30
– – ﹤0.01% 3752
2025
Q2 		$30 Hold
30
– – ﹤0.01% 3926
2025
Q1 		$44 Hold
30
– – ﹤0.01% 3391
2024
Q4 		$66 Buy
+30
New +$70 ﹤0.01% 3445

Other funds holding ESPR

Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

MAI Capital Management's ESPR Position: Q2 2026 in Review

MAI Capital Management sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 88 shares — an estimated $242 sold.

MAI Capital Management first reported a position in ESPR in Q4 2024 and held it in 6 quarters. The position peaked at $242 in Q1 2026. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • MAI Capital Management reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 88 Esperion Therapeutics shares in Q2 2026, an estimated $242.
  • MAI Capital Management first reported a position in Esperion Therapeutics in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Esperion Therapeutics position peaked at $242 in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.